Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Integrating the Idylla™ System Alongside a Real-Time Polymerase Chain Reaction and Next-Generation Sequencing for Investigating Gene Fusions in Pleural Effusions from Non-Small-Cell Lung Cancer Patients: A Pilot Study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
اقرأ على الانترنت اقرأ أكثر حفظ في قائمتي
  • معلومة اضافية
    • المصدر:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: Basel, Switzerland : MDPI, [2000-
    • الموضوع:
      Carcinoma, Non-Small-Cell Lung*/genetics ; Lung Neoplasms*/genetics ; Lung Neoplasms*/pathology ; High-Throughput Nucleotide Sequencing*/methods ; Real-Time Polymerase Chain Reaction*/methods; Humans ; Pilot Projects ; Male ; Female ; Aged ; Middle Aged ; Pleural Effusion, Malignant/genetics ; Pleural Effusion, Malignant/pathology ; Pleural Effusion, Malignant/diagnosis ; Oncogene Proteins, Fusion/genetics ; Gene Fusion ; Adult ; Mutation ; Anaplastic Lymphoma Kinase/genetics ; Aged, 80 and over ; Proto-Oncogene Proteins c-ret/genetics ; Protein-Tyrosine Kinases ; Proto-Oncogene Proteins
    • نبذة مختصرة :
      Malignant pleural effusion (MPE) from patients with advanced non-small-cell lung cancer (NSCLC) has been proven valuable for molecular analysis; however, simultaneous detection of driver fusions in MPE is still challenging. In this study, we investigated the Idylla™ GeneFusion Panel, a stand-alone test in tissue samples, in the evaluation of ALK , ROS1 , RET and MET ex14 skipping mutations in MPE and compared its performance with routine reference methods (Real-time-based and Next-generation Sequencing-NGS). The inclusion criteria for sample selection were as follows: advanced NSCLC harboring ALK , ROS1 , RET fusions or MET exon-skipping alterations and the availability of MPE collected at diagnosis or disease progression. Molecular alterations have been investigated on tissue by fluorescence in situ hybridization (FISH) or Real-time PCR or NGS. For molecular profiling with the Idylla™ GeneFusion, 200 µL of MPE supernatants combined with 50 µL of RNA Later solution were loaded into the Idylla™ cartridge without cfRNA extraction. The Idylla™ GeneFusion Assay performed on MPEs was able to confirm molecular profile, previously diagnosed with conventional methods, in all cases. Our data confirm that MPE are suitable material for investigating fusion alterations. The Idylla™ GeneFusion, although indicated for investigation of tissue samples, offers the possibility of performing a molecular characterization of supernatants without undertaking the entire cfRNA extraction procedure providing a rapid and reliable strategy for the detection of actionable genetic alterations.
    • References:
      Oncologist. 2011;16(6):877-85. (PMID: 21572125)
      JTO Clin Res Rep. 2022 Nov 09;3(12):100434. (PMID: 36536899)
      Thorac Cancer. 2019 Apr;10(4):823-831. (PMID: 30779318)
      Nat Rev Clin Oncol. 2011 Aug 23;8(11):661-8. (PMID: 21862980)
      Crit Rev Oncol Hematol. 2021 Jan;157:103194. (PMID: 33316418)
      Sci Rep. 2023 Aug 9;13(1):12909. (PMID: 37558711)
      Arch Pathol Lab Med. 2016 Jun 22;140(11):1191-1199. (PMID: 27333361)
      JCO Precis Oncol. 2022 Oct;6:e2200246. (PMID: 36315914)
      J Pers Med. 2021 Oct 27;11(11):. (PMID: 34834454)
      J Clin Med. 2021 Nov 26;10(23):. (PMID: 34884236)
      Curr Opin Pulm Med. 2021 Jul 1;27(4):249-254. (PMID: 33927132)
      Int J Mol Sci. 2021 Mar 05;22(5):. (PMID: 33807876)
      J Thorac Oncol. 2019 Dec;14(12):2046-2052. (PMID: 31757374)
      Cancers (Basel). 2022 Dec 31;15(1):. (PMID: 36612287)
      Mol Biol Rep. 2020 Oct;47(10):8179-8187. (PMID: 33029702)
      Respir Res. 2024 Jan 19;25(1):47. (PMID: 38243259)
      Lung Cancer. 2022 Oct;172:53-64. (PMID: 35998482)
      Cell Mol Life Sci. 2018 Sep;75(18):3381-3392. (PMID: 30003270)
    • Contributed Indexing:
      Keywords: Idylla™ system; NSCLC; cfRNA; gene fusion; malignant pleural effusion
    • الرقم المعرف:
      0 (Oncogene Proteins, Fusion)
      EC 2.7.10.1 (ROS1 protein, human)
      EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
      EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
      EC 2.7.10.1 (Protein-Tyrosine Kinases)
      0 (Proto-Oncogene Proteins)
    • الموضوع:
      Date Created: 20240727 Date Completed: 20240728 Latest Revision: 20240729
    • الموضوع:
      20240729
    • الرقم المعرف:
      PMC11277451
    • الرقم المعرف:
      10.3390/ijms25147594
    • الرقم المعرف:
      39062837